mesna and Lupus-Erythematosus--Systemic

Topics: Anaphylaxis; Angiotensin Receptor Antagonists; Female; Humans; Lupus Erythematosus, Systemic; Mesna; Middle Aged; Protective Agents

Mesna is used to abolish urotoxicity of cyclophosphamide and related compounds in immunosuppressive and antineoplastic treatment schedules. Adverse reactions to this drug have been reported only rarely.. Drug eruptions to mesna have developed in seven of 15 patients with autoimmune disorders treated with monthly pulses of intravenous cyclophosphamide. Two different types of drug eruptions were observed: five patients had development of a macular and partly papular or urticarial rash and angioedema and two patients had a generalized fixed drug eruption, primarily and predominantly at the sites of previous skin lesions of their underlying condition. The results of prick, patch, and intradermal tests were similar in both types of rash; however, the two patients with fixed drug eruption had developed a generalized eruption upon prick testing with mesna.. Two distinct eruptions to mesna have been induced in these patients during cyclophosphamide/corticosteroid therapy; these eruptions are not thought to share a common pathogenic mechanism. The results of skin and challenge tests do not support the hypothesis that a type 1 or a type 4 immune reaction may be responsible for these eruptions. The unusually high incidence (about 50%) of these reactions and their clinical presentation make it important to distinguish them from an exacerbation of the preexistent autoimmune disorder.

Topics: Adult; Biopsy; Cyclophosphamide; Dermatomyositis; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Lupus Erythematosus, Systemic; Male; Mesna; Methylprednisolone; Metoclopramide; Middle Aged; Patch Tests; Skin